Gufic BioSciences Ltd
Gufic BioSciences Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
3 of 4 strong
The short version
Gufic Biosciences expects a consistent revenue growth of around 15% year-over-year. Revenue is expected to grow at a minimum of 15% year-over-year, driven by both domestic and international markets.
From Gufic BioSciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Gufic Biosciences expects a consistent revenue growth of around 15% year-over-year.
- Domestic market growth driven by new product launches in critical care, IVF, botulinum toxin, orthopedics, gynecology, and pain management.
- International business growth fueled by marketing authorizations in Europe, South Africa, Canada, Brazil, and others, expanding both tender and private markets.
- Shift towards holding marketing authorizations internationally to improve margins and control.
- CMO business expected to grow modestly, with GLP-1 orders peaking soon; overall CMO share around 15%-18%.
- Backward integration and new molecule additions expected to enhance margins and stability.
2 more points from Gufic BioSciences Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Gufic BioSciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No major new greenfield capex is planned for the next 2 to 3 years; focus is on maintenance/replacement capex.
- Navsari facility will have annual replacement capex of around INR 20 crores to maintain operations.
- Investments have been made in Indore expansion and dossier/regulatory work, mostly completed.
- Clinical trial investments ongoing, e.g., INR 40-50 crores for a long-acting product and INR 15-20 crores for short-acting clinical trials, funded through internal cash flows without incurring new debt.
- Strategic new projects may arise but no large-scale capex is foreseen in near term.
2 more points from Gufic BioSciences Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gufic BioSciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention specific current or expected order book or pending orders by value or volume.
- Management discusses ongoing efforts in gaining marketing authorizations internationally and recruitment in international markets to support front-end business.
- There is reference to batches planned for U.S. FDA filings and inspections anticipated by the end of the year to initiate U.S. market operations around 2028-29.
- Expansion in various geographies (Europe, U.S., South Africa, Canada, Brazil) is expected to add incremental business with more molecules being introduced year-over-year.
2 more points from Gufic BioSciences Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Gufic BioSciences Ltd — Quarterly revenue & net profit
Q4 FY26 figures are not in this chart yet. Latest shown: Dec 2025 (Q3 FY26). The Q4 FY26 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹231 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gufic BioSciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pha. (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Arthneeti Pro · Annual
Gufic BioSciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gufic BioSciences Ltd Q4 FY26 results?
Gufic Biosciences expects a consistent revenue growth of around 15% year-over-year. Revenue is expected to grow at a minimum of 15% year-over-year, driven by both domestic and international markets.
What is Gufic BioSciences Ltd share price analysis?
Gufic BioSciences Ltd currently shows a below-average growth signal. The stock trades at a P/E of 62.6 with a market cap of ₹3,955 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gufic BioSciences Ltd planning capital expenditure?
No major new greenfield capex is planned for the next 2 to 3 years; focus is on maintenance/replacement capex.
Keep Gufic BioSciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.